ESC 365 - The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction

ACVC Premium Access

The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction

Session: Anti-thrombotic management in patients with acute coronary syndromes (ACS)

Topic: Pharmacotherapy

Speaker: Mr S. Rikken (Nieuwegein, NL)

Event: ESC Acute CardioVascular Care 2022

Congress Presentation

Add to my library

About the speaker

Mr Sem A O F Rikken

St Antonius Hospital, Nieuwegein (Netherlands (The))

1 follower

4 more presentations in this session

Antiplatelet pretreatment in NSTE-ACS: do we have the answer?

Speaker: Doctor P. Capranzano (Catania, IT)

Do we really need aspirin?

Speaker: Professor R. Mehran (New York, US)

Extended, standard or de-escalation antiplatelet therapy after ACS?

Speaker: Professor K. Huber (Vienna, AT)

Anti-thrombotic management in patients with acute coronary syndromes - discussion.

Access the full session

Anti-thrombotic management in patients with acute coronary syndromes (ACS)

Speakers: Mr S. Rikken, Doctor P. Capranzano, Professor R. Mehran, Professor K. Huber

About the event

ESC Acute CardioVascular Care 2022

18 March - 19 March 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources